PureTech announces receipt of FDA Fast Track Designation for LYT-200 in AML
PureTech Health (PRTC) announced that the U.S. Food and Drug Administration has granted Fast Track designation to LYT-200, a first-in-class anti-galectin-9 monoclonal antibody, for the treatment of acute myeloid leukemia.
PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced that the U.
PureTech Drug Gets FDA Fast-Track Designation for Leukemia
The biotherapeutics company said the treatment, LYT-200, is being evaluated in two ongoing clinical trials. It was previously granted orphan drug designation for the treatment of acute myeloid leukemia, as well as a separate fast-track designation for the treatment of recurrent/metastatic head and neck squamous cell carcinomas.
PureTech receives FDA fast track designation for leukemia treatment
(Alliance News) - PureTech Health PLC on Thursday said that the US Food & Drug Administration has granted fast track designation to its antibody LYT-200 for the treatment of acute myeloid leukemia. The designation aims to expedite the development and regulatory review of drugs addressing serious conditions with unmet medical needs.
PureTech Says FDA Grants Fast Track Designation For LYT-200 In Acute Myeloid Leukemia
Biotherapeutics company PureTech Health plc (PRTC) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted
PureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference
About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company ...
Business Insider25d
PureTech's Deupirfenidone Shows Positive Results In Slowing Lung Function Decline In IPF Patients
(RTTNews) - PureTech Health plc (PRTC, PRTC.L) announced positive results from the ELEVATE IPF trial. This Phase 2b, randomized, double-blind, active- and placebo-controlled, dose-ranging study ...
Hosted on MSN24d
PureTech sees success in Phase IIb Pulmonary Fibrosis trial
Boston-situated clinical-stage biotherapeutics company PureTech’s Phase IIb trial of deupirfenidone met all primary and secondary endpoints, slowing lung degeneration in patients with idiopathic ...
SourceSecurity22d
PureTech's RDAPSS: Autonomous perimeter surveillance
PureTech Systems Inc., a pioneer in geospatial AI-boosted video analytics for wide-area perimeter and border security, is proud to announce the launch of its Rapid Deploy Autonomous Perimeter ...
Business Wire25d
PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the ...
The two doses of deupirfenidone were chosen based on PureTech’s Phase 1 data, which showed that a 550 mg TID dose of deupirfenidone provided approximately equivalent drug exposure to pirfenidone ...
Yahoo Finance4d
PureTech Appoints UBS as UK Corporate Broker
PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad ...